NCT04373265View on ClinicalTrials.gov

Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

September 30, 2020

Primary Completion Date

October 17, 2023

Study Completion Date

January 12, 2024

Conditions
Adrenocortical Carcinoma
Interventions
DRUG

Relacorilant

Relacorilant, 100 mg soft gel capsules orally once daily

DRUG

Pembrolizumab

Pembrolizumab 400 mg infusion every 6 weeks

Trial Locations (6)

10022

Site #051, Memorial Hospital, New York

33612

Site #007, Moffitt Cancer Center, Tampa

48109

Site #074, University of Michigan Medical School, Ann Arbor

55905

Site #030 Mayo Clinic, Rochester

77030

Site #183, The University of Texas M.D. Anderson Cancer Center, Houston

94305

Site #150, Stanford Cancer Center, Stanford

Sponsors
All Listed Sponsors
lead

Corcept Therapeutics

INDUSTRY